azer-cel CAR-T naive data presented at ASCO Annual Meeting

IMUGENE LIMITED ACN 009 179 551 WWW.IMUGENE.COM [email protected] ASX Announcement Imugene’s azer-cel CAR-T naïve data presented at ASCO 2026 Annual Meeting • Azer-cel data presented by Dr Supriya Gupta, at the 2026 ASCO Annual Meeting, Chicago, the world’s leading oncology conference • Azer-cel was selected for oral presentation from more than 8,500 submissions • Full abstract available at asco.org/abstracts • Presentation available at imugene.com/investors/conference-presentations Sydney, Australia, 1 June 2026: Imugene Limited (ASX:IMU), a clinical-stage immuno- oncology company, is pleased to report that azer-cel (azercabtagene zapreleucel) Phase 1b clinical data has been presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. The data was presented by Dr Supriya Gupta, University of Minnesota in the Oral Abstract Session Hematologic Malignancies: Lymphoma and Chronic Lymphocytic Leukemia, on 29 May 2026 at 1:00 PM CDT. ASCO is the world’s leading oncology conference, with more than 40,000 oncology professionals, researchers, and investors attending globally each year. Of more than 8,500 abstracts submitted for consideration at the 2026 Annual Meeting, only a small proportion were selected for oral presentation which is a distinction awarded by ASCO’s peer reviewed Scientific Program Committee on the basis of clinical significance and scientific quality. Oral selection places azer-cel among the most significant data readouts of the conference. As demonstrated by the data presented at ASCO on 29 May, 2026; 25 patients in the CAR-T naive cohort with relapsed or refractory blood cancers received azer-cel in combination with low-dose IL-2, and 24 were evaluable for response following their first IMUGENE LIMITED ACN 009 179 551 2 disease assessment at Day 28. Among these 24 patients, responses were observed across all six cancer subtypes, including: • DLBCL: 67% response rate • MZL: 83% response rate • CLL: 100% response rate • PCNSL: 50% response rate • FL: 100% response rate • WM: 100% response rate Leslie Chong, Managing Director and CEO of Imugene, said: "The level of interest and depth of questioning from clinicians and researchers at our oral presentation at ASCO was genuinely encouraging. These are some of the most rigorous scientific minds in oncology, and the engagement we saw reflects growing recognition of azer-cel and its potential to offer patients further treatment options. We look forward to providing further updates as the data matures." The ASCO Presentation is available at imugene.com/investors/conference- presentations. The Phase 1b azer-cel clinical trial is a multi-cohort study evaluating patients with relapsed or refractory CD19-positive B-cell malignancies (blood cancers), including both CAR-T naïve and CAR-T relapsed/refractory cohorts. The study has recently expanded into Cohort 3, which evaluates azer-cel in concurrent dosing with Bruton Tyrosine Kinase inhibitors (BTKi). The first patient in this cohort was dosed on 28 May 2026. The trial is active across ten US sites and five Australian sites. Acronym Key: DLBCL: Diffuse Large B-Cell Lymphoma MZL: Marginal Zone Lymphoma CLL: Chronic Lymphocytic Leukemia PCNSL: Primary Central Nervous System Lymphoma FL: Follicular Lymphoma WM: Waldenström Macroglobulinemia IMUGENE LIMITED ACN 009 179 551 3 For more information please contact: Leslie Chong Managing Director and Chief Executive Officer [email protected] General Investor Enquiries [email protected] Media Enquiries [email protected] Connect with us on LinkedIn @Imugene Limited Watch us on YouTube @ImugeneLimited About Imugene (ASX:IMU) Imugene is a clinical stage cell therapy company developing an Allogeneic CAR-T for blood cancers. Our lead asset is an off-the-shelf (allogeneic) cell therapy CAR-T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. We are supported by a leading team of international cancer experts with extensive experience in developing novel cancer therapies. Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and together with leading specialists and medical professionals, we believe Imugene’s cellular therapy may become foundation treatments for cancer. Our goal is to ensure that Imugene is at the forefront of this rapidly growing global market. Release authorised by the Managing Director and Chief Executive Officer Imugene Limited.

The release as fetched from its publisher. weblink.com.au ↗